)
Visual
test
EXACT Therapeutics
EXACT Therapeutics (EXTX) investor relations material
EXACT Therapeutics Company presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company presentation summary5 Feb, 2026
Oncology development and clinical progress
PS101, a proprietary ultrasound-activated prodrug, demonstrated a 4x increase in tumor shrinkage versus standard of care in Phase 1 for liver metastases and showed excellent safety.
Ongoing Phase 2 ENACT trial in first-line locally advanced pancreatic cancer patients in the US and UK reported positive initial safety and early encouraging treatment responses.
Early ENACT data showed ≥85% reduction in CA 19-9 biomarker and up to 46% tumor shrinkage in initial patients, indicating strong clinical benefit potential.
PS101 enables targeted, organ-specific drug delivery through a non-invasive, ultrasound-activated process, enhancing chemotherapy effects.
The addressable patient population for the lead indication is approximately 30,000 annually in the USA and EU5.
Strategic focus and pipeline expansion
Core focus is on winning in locally advanced pancreatic cancer, with the ENACT Phase 2 trial as the top priority.
Preclinical pipeline includes gene therapy (nonviral delivery), CNS cancers, blood-brain barrier applications, and immuno-oncology combinations.
Preclinical studies show PS101 can open the blood-brain barrier and enhance delivery of various drug formulations.
Immuno-oncology applications and glioblastoma models are being explored, with promising preclinical results.
Broad IP coverage supports expansion into multiple therapeutic areas.
Financials, milestones, and outlook
Raised $13M in December 2024, with up to $6M more from warrant exercises expected in February 2026; 75% of this amount is already secured.
Use of proceeds includes securing the ENACT trial through key data points, expanding IP, and supporting non-clinical research.
Major milestones achieved include final Phase 1 results, regulatory approvals, and initial dosing in Phase 2.
Near-term news flow in 2026 includes publication of Phase 1 results, multiple ENACT trial readouts, and preclinical updates.
Partnership with a leading medical equipment company strengthens device and supply chain support.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
- 6 FebSCW
Q2 2025 revenue up 120% y/y, driven by record Asian contract and backlog growth.
Next EXACT Therapeutics earnings date
Investor update11 Feb, 2026
EXACT Therapeutics
Next EXACT Therapeutics earnings date
Investor update11 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
EXACT Therapeutics AS is a clinical-stage biopharmaceutical company headquartered in Oslo, Norway. The company is pioneering a novel ultrasound-mediated technology platform called Acoustic Cluster Therapy (ACT). This approach aims to significantly enhance the clinical utility of a wide range of therapeutic agents for a variety of applications, including oncology (both chemotherapy and immunotherapy), neurological conditions, and gene therapy. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage